Hepatotoxicity Associated With New BCR-ABL TKIs vs Imatinib Among Patients With Chronic Myeloid Leukemia
This systematic review and meta-analysis examines the relative risk of hepatotoxicity of new-generation BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (TKIs) vs imatinib among patients with chronic myeloid leukemia.